6IB Stock Overview
A biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Innovent Biologics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$3.96 |
| 52 Week High | HK$6.20 |
| 52 Week Low | HK$3.40 |
| Beta | 0.12 |
| 11 Month Change | -36.13% |
| 3 Month Change | -14.66% |
| 1 Year Change | -25.98% |
| 33 Year Change | -47.20% |
| 5 Year Change | 46.67% |
| Change since IPO | 98.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6IB | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -10.0% | -0.4% | -1.8% |
| 1Y | -26.0% | -15.4% | 13.6% |
Return vs Industry: 6IB underperformed the German Biotechs industry which returned -15.4% over the past year.
Return vs Market: 6IB underperformed the German Market which returned 13.6% over the past year.
Price Volatility
| 6IB volatility | |
|---|---|
| 6IB Average Weekly Movement | 10.1% |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6IB's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 6IB's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 5,263 | Michael Yu | www.innoventbio.com |
Innovent Biologics, Inc., a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People’s Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor. The company is also developing IBI-326, a fully-human BCMA CAR T-cell therapy; IBI-376, an oral inhibitor of PI3Kd; IBI-351, a KRASG12C inhibitor; IBI-344, a repressor of silencing 1/TRK tyrosine kinase inhibitor; IBI-126, an ADC targeting CEACAM5; IBI-306, a novel anti-proprotein convertase subtilisin/kexin type 9 enzyme monoclonal antibody; IBI-362, a glucagon-like peptide-1 receptor/glucagon receptor dual agonist; and IBI-112, a novel long-acting anti-IL-23.
Innovent Biologics, Inc. Fundamentals Summary
| 6IB fundamental statistics | |
|---|---|
| Market cap | €6.80b |
| Earnings (TTM) | -€166.04m |
| Revenue (TTM) | €966.27m |
7.0x
P/S Ratio-41.0x
P/E RatioIs 6IB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6IB income statement (TTM) | |
|---|---|
| Revenue | CN¥7.46b |
| Cost of Revenue | CN¥2.12b |
| Gross Profit | CN¥5.34b |
| Other Expenses | CN¥6.62b |
| Earnings | -CN¥1.28b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.78 |
| Gross Margin | 71.58% |
| Net Profit Margin | -17.18% |
| Debt/Equity Ratio | 25.8% |
How did 6IB perform over the long term?
See historical performance and comparison